Rejected from NEJM? 8 Similar Journals to Submit to Next

A rejection from the New England Journal of Medicine is the most common outcome for the manuscripts sent there, and it usually arrives quickly. Authors often read that speed as a verdict on the science. More often it is a verdict on fit: NEJM publishes a small number of original articles each week, and it declines many sound, competently run studies simply because they do not change practice enough for its general medical readership. If you are searching for journals like NEJM, the useful question is not which journal has the next highest prestige. It is which journal would plausibly want this particular paper.

This guide covers how to read your rejection, then walks through eight realistic next targets. I have deliberately avoided ranking them by any single number. Where a fact about acceptance rates, word limits or reference caps varies between secondary sources, I say so and send you to the journal's own instructions, which I could not open directly while preparing this post.

Read the Rejection Before You Choose Where Next

NEJM rejections fall into roughly three shapes, and each points somewhere different. A rapid decision without review, often within days, typically means the editors judged the question too narrow, the effect too small to alter practice, or the design unable to support a firm conclusion. A rejection after external review is rarer and more informative, because the reviewer comments are a free assessment of what a specialist audience will say. A rejection that suggests a more specialised journal is, despite how it feels, a genuine redirection.

Write down which of the three you received before you pick a target. A fast decline on a well-run trial with a modest, honest result usually fits a high-quality general journal or a strong specialty title. A decline that names a methodological weakness, such as short follow-up, a surrogate endpoint or a post hoc analysis, tells you to look for venues that value the contribution while being frank about the limitation. Resist the urge to resubmit within hours; a day spent rereading the letter will save weeks later.

One practical point: NEJM decisions do not publish their reasoning, and acceptance estimates circulating online (figures of five or six percent appear often) come from consultancy blogs rather than from NEJM itself. Treat them as orders of magnitude, not statistics you can plan around.

What Journals Like NEJM Actually Have in Common

NEJM is unusual in combining three features: a broad clinical readership, a strong preference for randomised or otherwise definitive evidence, and a very tight word budget. Journals that share two of the three are the sensible comparison set. General medical journals share the readership. Specialty flagships share the evidence standard. A handful of newer titles share the editorial style but narrow the scope.

That distinction matters because it tells you what to change before resubmitting. Moving to a journal with the same readership but a larger word allowance lets you restore detail you cut for NEJM. Moving to a specialty journal lets you reframe the discussion for experts who already accept the clinical background, which often shortens the introduction considerably.

Reporting expectations are broadly the same across all of them. If your trial followed CONSORT, your systematic review followed PRISMA or your cohort study followed STROBE, the checklist travels with you. You should not need to redo the science, only the framing and the format.

Eight Journals to Consider After an NEJM Rejection

The list below is grouped by the kind of fit it offers, not by a ranking. I have described each journal's general character from public knowledge of what it publishes. Check the current instructions for authors for word limits, reference caps and article types, because secondary guides disagree with each other on those numbers and journals revise them.

JAMA, the flagship of the JAMA Network, is the closest peer for general medical readership and for definitive clinical research, and it is a common second stop after NEJM. Its Original Investigation format is short and structured, with Key Points, so a manuscript trimmed for NEJM often converts without much change. The Lancet is similar in ambition and strongly favours trials with global health relevance, along with a distinctive requirement to describe the research in context of the prior evidence. The BMJ is a different animal: it values practical relevance to clinicians and health systems, publishes a wide range of study types, and asks authors for a short statement of what is already known and what the study adds.

Annals of Internal Medicine, published by the American College of Physicians, suits studies with direct implications for internal medicine practice and has a long record of publishing both trials and well-conducted systematic reviews. PLOS Medicine is a general medical journal with an open access model and a particular openness to global health, epidemiology and policy-relevant work. It can be a strong home for a study that would have been a hard sell at a journal focused on drug and device trials.

Within the NEJM family itself, NEJM Evidence is aimed at original research and ideas on clinical trial design and clinical decision-making, so a methodologically interesting trial can fit there when the flagship found it too specialised. NEJM AI is built for work where artificial intelligence or machine learning is the central contribution, so it is relevant only if your study is genuinely about a model, dataset or deployment. Beyond those, the JAMA Network specialty journals, including JAMA Network Open, offer a route that keeps you in a respected family with a distinct set of editors. Finally, Nature Medicine is a realistic target for translational and mechanistic clinical studies with a strong biological story, though its priorities differ from NEJM's and a pure practice-changing trial does not always suit it.

Match the Journal to the Study Type

The strongest predictor of a good outcome is whether your design matches what the journal usually publishes. A large pragmatic trial with a clear primary endpoint belongs with the general journals above. A secondary analysis of a trial, a cohort study with careful confounder control, or a registry analysis is more likely to be welcomed by JAMA Network Open or a specialty flagship, which publish a lot of observational work and explicitly invite it.

Systematic reviews and meta-analyses face a different filter. Annals and the BMJ have published them regularly, but they expect protocol registration (for example in PROSPERO) and adherence to PRISMA 2020. If yours was not registered, say so plainly and look for journals that do not make registration a condition of review. Our guide to PRISMA 2020 covers what that checklist expects.

Negative and null trials deserve a note. Several journals have stated that they evaluate studies on methodological quality, not on whether the result was positive. That is a reasonable basis for choosing, but read recent issues to see whether the practice matches the policy before you rely on it.

Adapt the Manuscript Before You Resubmit

A paper written to NEJM's tight limit often has material you cut that now belongs back in the text: secondary outcomes, limitations, subgroup detail, and a fuller methods section. A paper going to a specialty journal may need the opposite, a clearer statement of why a clinician outside the field should care. Rewrite the first paragraph of the introduction and the first paragraph of the discussion for the new audience. Editors notice when a cover letter and abstract still address a different journal.

Update the cover letter with a specific reason this journal is the right one, drawn from its recent content, not a generic compliment. Remove any reference to the earlier rejection unless the journal asks about previous submissions; it is not required in most cases, and if you were offered reviewer reports, you may choose to use them to improve the manuscript privately. Our guide on responding to reviewer comments and the post on what to do after journal rejection are useful for this stage.

Finally, reformat to the new journal's structure. Abstract length, Key Points or Plain Language Summary, trial registration statements, data sharing statements and author contribution formats all differ. A manuscript that arrives in the right format signals that the authors are careful, and it avoids an administrative return that costs days.

Timing, Cascades and the Cost of Going Down the Ladder

Authors often submit sequentially down a list, losing a few weeks each time. That is usually the right instinct, since simultaneous submission is prohibited by essentially every journal and by ICMJE recommendations. What you can do is shorten each cycle by preparing a second version of the manuscript while the first is still under consideration, so that a rejection costs a day of cover-letter editing and not a month of rewriting.

Be realistic about how many steps the study can afford. A trial that reports a time-sensitive result loses value with each delay, particularly if a competing trial is reading out. In that case, a strong journal with a faster decision process may serve the work better than a slightly more famous one. Preprints are an option for some studies, though policies vary by journal, so check before posting.

Our post on journal manuscript transfer cascades explains how publishers move papers within their portfolios, and what you give up when you accept a transfer.

Frequently Asked Questions

Can I submit to a journal like NEJM at the same time as another journal? No. Concurrent submission of the same work is prohibited by the ICMJE recommendations and by the policies of virtually every medical journal. Wait for a decision first.

Is a fast NEJM rejection a bad sign for the paper? Not necessarily. A rapid decline most often reflects scope and priority, not scientific flaws. It does mean you should not treat the paper as an automatic fit for the next journal at the same tier without reading its recent issues.

Are NEJM alternatives always lower in standing? No. Many are at a similar level and differ mainly in audience or article type. Sorting by fit tends to produce better outcomes than sorting by prestige.

A Practical Plan for the Next Seven Days

Reread the decision letter and classify it. Pick three candidate journals and read five recent articles from each that resemble your design. Check the current author instructions for article type, length and mandatory statements. Rewrite the abstract and first paragraphs for the chosen audience, rework the cover letter, and submit. If the second choice also declines, you will already hold a formatted version for the third.

The goal is not to lower your ambitions. It is to put a good paper in front of editors who are looking for exactly that kind of work. Most clinical research that is publishable at all finds a home, and the authors who get there fastest are the ones who treat the first rejection as information.

Further Reading